Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen BioNTech BNTX

BioNTech live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Global finance
Neil Wilson 2024 Nov 14, 17:00

Fed Hints at Tight Policy Amid Global Economic Uncertainty

Fed
Frances Wang 2024 Nov 14, 16:00

Dogecoin surges after Elon Musk issues crypto endorsement

Cryptocurrencies
Nvidia Blackwell AI Chips
Neil Wilson 2024 Nov 14, 16:00

Week ahead: Tech rally hinges on Nvidia earnings

Forex Indices
Frances Wang 2024 Nov 14, 16:00

Stock Market Today: Indexes Drop as Fed Rate Cuts are still underway

Fed Stocks
Frances Wang 2024 Nov 14, 16:00

What's Going On With Amazon Stock today? Is AMZN expected to rise?

Stocks AMZN
Dogecoin surges
Neil Wilson 2024 Nov 13, 17:00

Dogecoin surges as Trump unveils new government efficiency initiative with Musk andRamaswamy

Cryptocurrencies
Frances Wang 2024 Nov 13, 16:00

Japanese Yen to USD: Yen drops to fresh multi-month low against USD

Forex
Frances Wang 2024 Nov 13, 16:00

Asia markets today: Nikkei 225 up 0.18%, Hang Seng Index falls by 197 points

Indices

Info

Spread

0.7452

Spread (%)

0.7540 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt openen

Vrijdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

24827473920

Uitstaande aandelen

239740000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

2022-06-17

Ex-dividenddatum

2022-06-02

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-1.92

Meer informatie over dit instrument

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat